Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Nov;93(11):1398-405.
doi: 10.1136/hrt.2006.106955. Epub 2007 Feb 19.

Disease management programme for secondary prevention of coronary heart disease and heart failure in primary care: a cluster randomised controlled trial

Kamlesh Khunti  1 , Margaret Stone, Sanjoy Paul, Jan Baines, Louise Gisborne, Azhar Farooqi, Xiujie Luan, Iain Squire
Affiliations
Randomized Controlled Trial

Disease management programme for secondary prevention of coronary heart disease and heart failure in primary care: a cluster randomised controlled trial

Kamlesh Khunti et al. Heart. 2007 Nov.

Abstract

Aims: To evaluate the effect of a disease management programme for patients with coronary heart disease (CHD) and chronic heart failure (CHF) in primary care.

Methods: A cluster randomised controlled trial of 1316 patients with CHD and CHF from 20 primary care practices in the UK was carried out. Care in the intervention practices was delivered by specialist nurses trained in the management of patients with CHD and CHF. Usual care was delivered by the primary healthcare team in the control practices.

Results: At follow up, significantly more patients with a history of myocardial infarction in the intervention group were prescribed a beta-blocker compared to the control group (adjusted OR 1.43, 95% CI 1.19 to 1.99). Significantly more patients with CHD in the intervention group had adequate management of their blood pressure (<140/85 mm Hg) (OR 1.61, 95% CI 1.22 to 2.13) and their cholesterol (<5 mmol/l) (OR 1.58, 95% CI 1.05 to 2.37) compared to those in the control group. Significantly more patients with an unconfirmed diagnosis of CHF had a diagnosis of left ventricular systolic dysfunction confirmed (OR 4.69, 95% CI 1.88 to 11.66) or excluded (OR 3.80, 95% CI 1.50 to 9.64) in the intervention group compared to the control group. There were significant improvements in some quality-of-life measures in patients with CHD in the intervention group.

Conclusions: Disease management programmes can lead to improvements in the care of patients with CHD and presumed CHF in primary care.

PubMed Disclaimer

Conflict of interest statement

Competing interests: KK, IS and AF have received sponsorship for attending conferences and small honoraria from pharmaceutical companies that make beta‐blockers, ACE inhibitors and angiotensin receptor blockers. JB and LG have received sponsorship for attending conferences from these companies.

Comment in

References

    1. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997181231–1248. - PubMed
    1. Unal B, Critchley J A, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 20041091101–1107. - PubMed
    1. Ergin A, Muntner P, Sherwin R.et al Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States. Am J Med 2004117219–227. - PubMed
    1. EUROSPIRE II Study Group Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 200122554–572. - PubMed
    1. Campbell N C, Thain J, Deans H G.et al Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ 19983161430–1434. - PMC - PubMed

Publication types

MeSH terms

Substances